<DOC>
	<DOCNO>NCT01360086</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , cisplatin , leucovorin calcium , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving one drug ( combination chemotherapy ) together cetuximab surgery may make tumor small reduce amount normal tissue need remove . Giving drug surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study side effect give fluorouracil , cisplatin , leucovorin calcium together cetuximab see well work treat patient adenocarcinoma stomach gastroesophageal junction .</brief_summary>
	<brief_title>Fluorouracil , Cisplatin , Leucovorin Calcium , Cetuximab Treating Patients With Adenocarcinoma Stomach Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate objective response rate accord RECIST V1.1 criterion patient adenocarcinoma stomach gastroesophageal junction treat neoadjuvant chemotherapy comprise fluorouracil , cisplatin , leucovorin calcium , cetuximab follow surgery adjuvant chemotherapy . - To determine non-toxicity rate patient . Secondary - To determine rate macroscopically microscopically complete surgical resection ( R0 ) . - To determine overall tolerance patient treat regimen . - To determine post-operative mortality morbidity patient . - To determine rate recurrence 1 2 year patient . - To determine recurrence-free survival 3 year patient . - To determine disease-free survival 3 year patient . - To determine overall survival 3 year patient . - To determine quality life use EORTC QLC-C30 STO-22 questionnaire . - To determine correlation response rate degree skin toxicity . OUTLINE : This multicenter study . - Neoadjuvant therapy surgery : Patients receive leucovorin calcium IV 2 hour , cisplatin IV , fluorouracil IV continuously 46 hour , cetuximab IV 1-2 hour day 1 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Within 3-4 week complete neoadjuvant chemotherapy , patient undergo surgery . - Adjuvant therapy : Within 4-8 week complete neoadjuvant chemotherapy , patient receive leucovorin calcium , cisplatin , fluorouracil , cetuximab neoadjuvant therapy . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Patients complete quality-of-life questionnaire ( QLC-C30 STO-22 ) periodically . Blood tissue sample collect periodically correlative translational study . After complete study therapy , patient follow every 4 month 2 year every 6 month 1 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma stomach gastroesophageal junction Stage IB , II , III disease accord TNM classification OR type I , II , III disease accord Siewert classification TNM : T1N13 , T2N03 , T3N03 , T4N03 ( T1N0 M1 ) Disease consider operable curative intent No gastric scirrhous carcinoma ( linitis plastica ) Forms independent cell consider linitis Measurable disease accord RECIST V1.1 No plan esophagectomy without thoracotomy patient adenocarcinoma gastroesophageal junction type I PATIENT CHARACTERISTICS : WHO performance status 02 Polynuclear neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine clearance &gt; 50 mL/min Bilirubin &lt; 1.5 time normal Serum albumin &gt; 30 g/L Prothrombin time ≥ 80 % FEV1 &gt; 1 L case thoracotomy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No know cirrhosis No progressive condition stabilize include follow : Hepatic failure Renal failure Respiratory failure NYHA class IIIIV congestive heart failure Unstable angina Myocardial infarction past 6 month Significant arrhythmias past 12 month No recent weight loss exceed 15 % No interstitial pneumonia No malignant tumor within past 5 year except basal cell skin carcinoma cancer situ cervix No psychological , familial , geographical reason preclude patient monitor regularly No person deprive liberty guardianship ( Disability Act ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy gastric cancer No concurrent anticancer treatment , immunotherapy , hormone therapy No prior abdominal thoracic radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IB gastric cancer</keyword>
	<keyword>stage IIA gastric cancer</keyword>
	<keyword>stage IIB gastric cancer</keyword>
	<keyword>stage IIIA gastric cancer</keyword>
	<keyword>stage IIIB gastric cancer</keyword>
	<keyword>stage IIIC gastric cancer</keyword>
</DOC>